Morgan Stanley Maintains Overweight on Elevance Health, Lowers Price Target to $551
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained an Overweight rating on Elevance Health but has lowered the price target from $643 to $551.
October 23, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Elevance Health, indicating continued confidence in the stock, but has lowered the price target from $643 to $551, suggesting a more conservative outlook.
The Overweight rating suggests that Morgan Stanley still sees potential in Elevance Health, but the lowered price target indicates a more cautious approach, possibly due to market conditions or company performance. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100